Allegro
What it found
The trial ended early for another reason (see below).
What was tested
Treatment tested
What it measured
Main measures
The study's primary endpoint is the number of confirmed relapses during the double blind treatment phase.
Relapses
Who could take part
Relapsing MS
Inclusion: 1. Subjects must have a confirmed and documented MS diagnosis as defined by the Revised McDonald criteria [Ann Neurol 2005: 58:840-846], with a relapsing-remitting disease course. Exclusion: 1. Subjects with progressive forms of MS
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To assess the efficacy of 0.6 mg daily dose of laquinimod compared to placebo in RRMS subjects, as measured by the number of confirmed relapses during the core study period.
Loading reviews and guidelines…
Related trials
- LTS18002
Phase 3 · Not yet recruiting
Still running
- FREXALT
Phase 3 · Running, not recruiting
Still running
- LITMUS
Not a drug-phase study · Completed (inferred)
Results posted, no main test reported
- Efficacy and Safety Study of Dapirolizumab pegol (BIIB133) in Participants with RMS
Phase 2 · Stopped early
Stopped early
- SUSTAIN
Phase 3 · Stopped early
Stopped early
- ZEUS
Not a drug-phase study · Stopped
Stopped early
History
Started
Jul 2007
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error